It	O	0,2
is	O	3,5
customary	O	6,15
to	O	16,18
divide	O	19,25
Lyme	B-KP	26,30
disease	I-KP	31,38
into	O	39,43
three	O	44,49
stages.	O	50,57

The	O	58,61
“primary	B-KP	63,71
lesion”	O	72,79
or	O	80,82
early	O	83,88
localized	O	89,98
stage	O	99,104
occurs	O	105,111
at	O	112,114
the	O	115,118
site	O	119,123
of	O	124,126
Borrelia	I-KP	127,135
inoculation.	O	136,148

The	O	149,152
infection	O	153,162
is	O	163,165
manifest	O	166,174
as	O	175,177
erythema	I-KP	178,186
migrans	I-KP	187,194
(migrating	O	195,205
redness),	O	206,215
an	O	216,218
erythematous	I-KP	219,231
papule	I-KP	232,238
that	O	239,243
expands	O	244,251
centrifugally	O	252,265
over	O	266,270
days	O	271,275
to	O	276,278
become	O	279,285
a	B-KP	287,288
plaque,	O	289,296
with	O	297,301
or	O	302,304
without	O	305,312
central	O	313,320
clearing	O	321,329
(Fig.	O	330,335

2).	O	336,339

With	O	340,344
the	O	345,348
development	O	349,360
of	B-KP	362,364
EM,	O	365,368
the	O	369,372
patient	O	373,380
may	O	381,384
also	O	385,389
have	O	390,394
constitutional	O	395,409
symptoms	O	410,418
such	O	419,423
as	B-KP	424,426
fever,	O	427,433
malaise,	O	434,442
and	B-KP	444,447
headache.	O	448,457

The	B-KP	458,461
skin	I-KP	462,466
lesion	O	467,473
may	O	474,477
have	O	478,482
localized	O	483,492
pain	O	493,497
or	I-KP	498,500
pruritus,	O	501,510
and	B-KP	511,514
regional	I-KP	515,523
lymphadenopathy	O	524,539
may	O	540,543
develop.	O	544,552

In	O	553,555
~20%	O	556,560
of	O	561,563
untreated	O	564,573
subjects,	O	574,583
this	O	584,588
early	O	589,594
stage	O	595,600
with	B-KP	602,606
EM	O	607,609
remains	O	610,617
the	O	618,621
only	O	622,626
manifestation	O	627,640
of	I-KP	641,643
Lyme	I-KP	644,648
disease.	O	649,657

In	O	658,660
the	O	661,664
first	O	665,670
few	O	671,674
weeks	O	675,680
after	O	681,686
infection,	O	687,697
spirochetes	O	698,709
can	O	710,713
be	O	714,716
cultured	O	717,725
from	O	726,730
blood	O	731,736
of	O	737,739
up	O	740,742
to	O	743,745
45%	O	746,749
of	O	750,752
American	O	753,761
patients,	O	762,771
indicating	O	772,782
that	O	783,787
they	O	788,792
disseminate	O	793,804
via	O	805,808
the	O	809,812
bloodstream	O	813,824
to	O	825,827
other	O	828,833
tissues	O	834,841
[101-103].	O	842,852

Note,	O	853,858
however,	O	859,867
that	O	868,872
culture	O	873,880
isolation	O	881,890
from	O	891,895
blood	O	896,901
is	O	902,904
much	O	905,909
less	O	910,914
frequently	O	915,925
achieved	O	926,934
in	O	935,937
European	O	938,946
patients	O	947,955
(0.7-7.7%)	O	956,966
[104-106],	O	967,977
possibly	O	978,986
suggesting	O	987,997
other	O	998,1003
routes	O	1004,1010
of	O	1011,1013
dissemination.	O	1014,1028

The	B-KP	1029,1032
“secondary	I-KP	1033,1043
lesions”	O	1044,1052
of	I-KP	1053,1055
Borrelia	I-KP	1056,1064
infection,	O	1065,1075
the	O	1076,1079
early	O	1080,1085
disseminated	O	1086,1098
stage,	O	1099,1105
comprises	O	1106,1115
multiple	O	1116,1124
EM	I-KP	1125,1127
lesions,	O	1128,1136
widespread	O	1137,1147
erythematous	I-KP	1148,1160
plaques	O	1161,1168
that	O	1169,1173
are	O	1174,1177
smaller	O	1178,1185
but	O	1186,1189
morphologically	O	1190,1205
similar	O	1206,1213
to	O	1214,1216
the	O	1217,1220
initial	O	1221,1228
lesion.	O	1229,1236

The	O	1237,1240
early	O	1241,1246
disseminated	O	1247,1259
stage	O	1260,1265
may	O	1266,1269
also	O	1270,1274
be	O	1275,1277
associated	O	1278,1288
with	B-KP	1289,1293
Lyme	I-KP	1294,1298
neuroborreliosis	O	1299,1315
(LNB),	O	1316,1322
and	I-KP	1323,1326
carditis.	O	1327,1336

European	O	1337,1345
patients	O	1346,1354
may	O	1355,1358
also	O	1359,1363
develop	O	1364,1371
a	I-KP	1372,1373
skin	I-KP	1374,1378
lesion	O	1379,1385
called	B-KP	1388,1394
borrelial	I-KP	1395,1404
lymphocytoma	O	1405,1417
during	O	1418,1424
this	O	1425,1429
stage	O	1430,1435
(Fig.	O	1436,1441

3).	B-KP	1444,1447

The	I-KP	1448,1451
“tertiary	I-KP	1452,1461
skin	O	1462,1466
lesion”	O	1467,1474
of	O	1475,1477
this	O	1478,1482
infection,	O	1483,1493
identified	O	1494,1504
for	O	1505,1508
decades	O	1509,1516
before	O	1517,1523
the	O	1524,1527
association	O	1528,1539
with	I-KP	1540,1544
Borreliawas	O	1545,1556
known,	B-KP	1558,1564
is	I-KP	1565,1567
acrodermatitis	I-KP	1568,1582
chronic	I-KP	1583,1590
atrophicans,	O	1591,1603
a	O	1604,1605
focal	O	1606,1611
area	I-KP	1612,1616
of	I-KP	1617,1619
atrophic	O	1620,1628
skin	O	1629,1633
usually	O	1634,1641
involving	O	1642,1651
an	O	1652,1654
extremity.	B-KP	1656,1666

Acordermatitis	I-KP	1667,1681
chronica	I-KP	1682,1690
atrophicans	B-KP	1693,1704
(ACA)	O	1705,1710
is	O	1711,1713
primarily	O	1714,1723
found	O	1724,1729
in	O	1730,1732
Europe,	O	1733,1740
and	O	1741,1744
is	O	1745,1747
most	O	1748,1752
commonly	O	1753,1761
associated	O	1762,1772
with	O	1773,1777
the	O	1778,1781
late	O	1782,1786
disseminated	O	1787,1799
stage,	O	1800,1806
which	O	1807,1812
can	O	1813,1816
also	O	1817,1821
include	O	1822,1829
late	O	1830,1834
neurological	O	1835,1847
manifestations.	O	1848,1863

Although	O	1864,1872
LA	O	1873,1875
can	O	1876,1879
occur	O	1880,1885
during	O	1886,1892
the	O	1893,1896
early	O	1897,1902
disseminated	O	1903,1915
stage,	O	1916,1922
it	O	1923,1925
is	O	1926,1928
more	O	1929,1933
commonly	O	1934,1942
observed	O	1943,1951
during	O	1952,1958
the	O	1959,1962
late	O	1963,1967
disseminated	O	1968,1980
stage.	O	1981,1987

